Accuray (ARAY) 10-Q 7 May 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Mar. 31, 2014	2-May-14
Document and Entity Information	'	'
Entity Registrant Name	'ACCURAY INC	'
Entity Central Index Key	'0001138723	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--06-30	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	76,764,330
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$88,013	$73,313
Short-term investments	86,009	101,084
Restricted cash	2,960	2,728
Accounts receivable, net of allowance for doubtful accounts of $1,250 and $2,160, respectively	59,264	55,458
Inventories	95,088	81,592
Prepaid expenses and other current assets	17,939	12,595
Deferred cost of revenue	10,408	9,165
Total current assets	359,681	335,935
Property and equipment, net	34,539	34,733
Goodwill	58,102	59,368
Intangible assets, net	25,506	31,896
Deferred cost of revenue	2,296	2,149
Other assets	10,948	11,848
Total assets	491,072	475,929
Current liabilities:	'	'
Accounts payable	18,139	15,920
Accrued compensation	25,602	12,461
Other accrued liabilities	21,689	22,893
Customer advances	22,341	17,692
Deferred revenue	90,602	86,893
Total current liabilities	178,373	155,859
Long-term liabilities:	'	'
Long-term other liabilities	5,599	5,382
Deferred revenue	8,985	9,085
Long-term debt	202,287	198,768
Total liabilities	395,244	369,094
Commitment and contingencies (Note 5)	'	'
Stockholders' Equity:	'	'
Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issued and outstanding	'	'
Common stock, $0.001 par value; authorized: 200,000,000 shares as of March 31, 2014 and June 30, 2013, respectively; issued and outstanding: 76,706,479 and 74,587,231 shares at March 31, 2014 and June 30, 2013, respectively	77	75
Additional paid-in capital	438,661	424,524
Accumulated other comprehensive income	2,375	1,882
Accumulated deficit	-345,285	-319,646
Total stockholders' equity	95,828	106,835
Total liabilities and stockholders' equity	$491,072	$475,929

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Condensed Consolidated Balance Sheets	'	'
Accounts receivable, allowance for doubtful accounts (in dollars)	$1,250	$2,160
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized shares	200,000,000	200,000,000
Common stock, issued shares	76,706,479	74,587,231
Common stock, outstanding shares	76,706,479	74,587,231

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Net revenue:	'	'	'	'
Products	$47,045	$25,023	$121,761	$98,821
Services	50,099	45,524	145,658	132,253
Total net revenue	97,144	70,547	267,419	231,074
Cost of revenue:	'	'	'	'
Cost of products	25,255	18,403	68,836	60,976
Cost of services	32,185	32,091	94,230	99,743
Total cost of revenue	57,440	50,494	163,066	160,719
Gross profit	39,704	20,053	104,353	70,355
Operating expenses:	'	'	'	'
Research and development	13,763	15,697	40,148	51,510
Selling and marketing	15,310	12,646	44,026	41,296
General and administrative	11,106	16,745	33,656	45,479
Total operating expenses	40,179	45,088	117,830	138,285
Loss from operations	-475	-25,035	-13,477	-67,930
Other expense, net	-3,312	-5,565	-9,547	-8,849
Loss before provision for income taxes	-3,787	-30,600	-23,024	-76,779
Provision for income taxes	878	603	2,615	1,867
Loss from continuing operations	-4,665	-31,203	-25,639	-78,646
Loss from discontinued operations (Note 9):	'	'	'	'
Loss from operations of a discontinued variable interest entity	'	'	'	-3,505
Impairment of indefinite lived intangible asset of discontinued variable interest entity	'	'	'	-12,200
Loss from deconsolidation of a variable interest entity	'	'	'	-3,442
Loss from discontinued operations, net of tax of $0	'	'	'	-19,147
Loss from discontinued operations attributable to non-controlling interest	'	'	'	-13,289
Loss from discontinued operations attributable to stockholders	'	'	'	-5,858
Net loss attributable to stockholders	-4,665	-31,203	-25,639	-84,504
Loss per share attributable to stockholders	'	'	'	'
Basic and diluted - continuing operations (in dollars per share)	($0.06)	($0.42)	($0.34)	($1.08)
Basic and diluted - discontinued operations (in dollars per share)	'	'	'	($0.08)
Basic and diluted - net loss (in dollars per share)	($0.06)	($0.42)	($0.34)	($1.16)
Weighted average common shares used in computing loss per share	'	'	'	'
Basic and diluted (in shares)	76,382	74,016	75,447	72,953
Net loss attributable to stockholders	-4,665	-31,203	-25,639	-84,504
Foreign currency translation adjustment	-121	-82	102	-446
Unrealized gain on investments, net of tax	32	'	391	'
Comprehensive loss	($4,754)	($31,285)	($25,146)	($84,950)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013
Condensed Consolidated Statements of Operations and Comprehensive Loss	'
Loss from discontinued operations, tax	$0

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash Flows From Operating Activities	'	'
Loss from continuing operations	($25,639)	($78,646)
Loss from discontinued operations	'	-19,147
Adjustments to reconcile net loss to net cash used in operating activities :	'	'
Depreciation and amortization	15,546	19,845
Impairment of indefinite lived intangible asset	'	12,200
Share-based compensation	8,243	6,119
Amortization of debt issuance costs	1,053	451
Amortization of premium on investments	1,296	'
Accretion of interest on long-term debt	3,519	3,192
Provision for (recovery of) bad debt	-546	-317
Provision for write-down of inventories	2,092	1,718
Loss on disposal of property and equipment	90	585
Gain on previously held equity interest in Morphormics	'	-662
Loss from deconsolidation of a variable interest entity	'	3,442
Changes in assets and liabilities:	'	'
Restricted cash	-173	-1,050
Accounts receivable	-1,988	13,238
Inventories	-14,841	-12,248
Prepaid expenses and other assets	-5,219	242
Deferred cost of revenue	-1,374	-2,333
Accounts payable	2,329	-2,197
Accrued liabilities	10,940	-12,313
Customer advances	4,226	-2,185
Deferred revenue	1,280	8,125
Net cash provided by (used in) operating activities	834	-61,941
Cash Flows From Investing Activities	'	'
Purchases of property and equipment, net	-9,615	-11,621
Purchase of intangible asset	'	-232
Purchase of investments	-30,422	'
Sale and maturity of investments	44,593	'
Acquisition of business, net of cash acquired (note 6)	'	-3,861
Net cash provided by (used in) investing activities	4,556	-15,714
Cash Flows From Financing Activities	'	'
Proceeds from employee stock plans	7,414	5,555
Taxes paid related to net share settlement of equity awards	-220	'
Proceeds from debt, net of costs	'	110,462
Net cash provided by financing activities	7,194	116,017
Effect of exchange rate changes on cash and cash equivalents	2,116	-340
Net increase in cash and cash equivalents	14,700	38,022
Cash and cash equivalents at beginning of period	73,313	143,504
Cash and cash equivalents at end of period	$88,013	$181,526

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	1. Summary of Significant Accounting Policies
	Description of Business
	Accuray Incorporated (together with its subsidiaries, the “Company” or “Accuray”) is incorporated in Delaware. The Company designs, develops and sells advanced radiosurgery and radiation therapy systems for the treatment of tumors throughout the body. The Company conducts its business worldwide. The Company has its headquarters in Sunnyvale, California, with additional locations worldwide.
	Basis of Presentation and Principles of Consolidation
	The condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and a variable interest entity, Compact Particle Acceleration Corporation (“CPAC”) until its deconsolidation on December 21, 2012 (for further information, see Note 9). All significant inter-company transactions and balances have been eliminated in consolidation.
	The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. The results for the three and nine months ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending June 30, 2014, for any other interim period or for any future year.
	These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the year ended June 30, 2013 included in the Company’s Annual Report on Form 10-K filed with the SEC. The Company’s significant accounting policies are described in Note 2 to those audited consolidated financial statements.
	Recently Issued Accounting Standards
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU No. 2013-11 requires that entities with an unrecognized tax benefit and a net operating loss carryforward or similar tax loss or tax credit carryforward in the same jurisdiction as the uncertain tax position present the unrecognized tax benefit as a reduction of the deferred tax asset for the loss or tax credit carryforward rather than as a liability, when the uncertain tax position would reduce the loss or tax credit carryforward under the tax law, thereby eliminating diversity in practice regarding this presentation issue. This new guidance is effective prospectively for annual reporting periods beginning on or after December 15, 2013, although retrospective application is permitted. The Company is currently assessing the impact of this guidance, if any, on its condensed consolidated financial statements.
	In March 2013, the FASB issued ASU No. 2013-05, Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. This new standard is intended to resolve diversity in practice regarding the release into net income of a cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. ASU No. 2013-05 is effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The Company is currently reviewing this standard, but it does not anticipate that its adoption will have a material impact on the Company’s condensed consolidated financial statements.
	Use of Estimates
	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures at the date of the financial statements. Key estimates and assumptions made by the Company relate to revenue recognition, the fair value of assets acquired and liabilities assumed in business combinations, asset impairments, inventories, share-based compensation expense, income taxes, loss contingencies and corporate bonus expenses. Actual results could differ materially from those estimates.
	Concentration of Credit and Other Risks
	The Company’s cash, cash equivalents and investments are deposited with several major financial institutions. At times, deposits in these institutions exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances.
	For the three and nine months ended March 31, 2014 and 2013, there were no customers that represented 10% or more of total net revenue. At March 31, 2014, one customer accounted for 15% of the Company’s total accounts receivable. At June 30, 2013, one customer accounted for 10% of accounts receivable.
	Accounts receivable are typically not collateralized. The Company performs ongoing credit evaluations of its customers and maintains reserves for potential credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Accounts are charged against the allowance for doubtful accounts once collection efforts are unsuccessful.
	Single source suppliers presently provide the Company with several components. In most cases, if a supplier was unable to deliver these components, the Company believes that it would be able to find other sources for these components subject to any regulatory qualifications, if required.
	Revenue Recognition
	The Company earns revenue from the sale of products, the provision of related services, which include post-contract customer support (“PCS”), installation services, training and other professional services, and the operation of its shared ownership program. The Company records its revenues net of any value added or sales tax. For arrangements with multiple elements, the Company allocates arrangement fees to product and services based upon Vendor Specific Objective Evidence (“VSOE”) of fair value of the respective elements, Third-Party Evidence (“TPE”), or Best Estimate of Selling Price (“BESP”), using the relative selling price method.
	Product and Service Revenue
	The majority of product revenue is generated from sales of CyberKnife and TomoTherapy systems. If the Company is responsible for installation, the Company recognizes revenue after installation and acceptance of the system. Otherwise, revenue is recognized upon delivery, assuming all other revenue recognition criteria are met.
	The Company could sell its systems with PCS contracts, installation services, training, and professional services. PCS contracts provide planned and corrective maintenance services, software updates, bug fixes, as well as call-center support. Service revenue is generated primarily from PCS (warranty period services and post warranty services), installation services, training, and professional services. PCS revenue is deferred and recognized over the service period. Installation service revenue is recognized concurrent with system revenue. Training and professional service revenues that are not deemed essential to the functionality of the systems are recognized as such services are performed.
	Costs associated with service revenue are expensed when incurred, except when those costs are related to system upgrades where revenue recognition has been deferred. In those cases, the costs are deferred and are recognized over the period of revenue recognition.
	Shared Ownership Program
	The Company also enters into arrangements under its shared ownership program with certain customers. These arrangements typically have a term of five years and provide the customer an option to purchase the system during the contractual term at pre-determined prices. Under the terms of this program, the Company retains title to its system, while the customer has use of the system. The Company generally receives a minimum monthly payment and earns additional revenues from the customer based upon its use of the system which are included in product revenue in the condensed consolidated statements of operations and comprehensive loss.
	Net Loss Per Common Share
	Basic and diluted net loss per share is computed by dividing net loss attributable to stockholders by the weighted average number of common shares outstanding during the period.
	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to stockholders follows (in thousands):
		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
	Numerator:
	Loss from operations used in computing loss per share from continuing operations	$	(4,665	)	$	(31,203	)	$	(25,639	)	$	(78,646	)
	Loss from discontinued operations used in computing loss per share from discontinued operations	$	—		$	—		$	—		$	(5,858	)
	Net loss used in computing net loss per share	$	(4,665	)	$	(31,203	)	$	(25,639	)	$	(84,504	)
	Denominator:
	Weighted average shares used in computing basic and diluted loss per share	76,382			74,016			75,447			72,953
	The potentially dilutive shares of the Company’s common stock resulting from the assumed exercise of outstanding stock options, the vesting of Restricted Stock Units (RSUs), Market Stock Units (MSUs) and Performance-based Stock Units (PSUs), and the purchase of shares under the Employee Stock Purchase Plan (ESPP), as determined under the treasury stock method, are excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive. The 3.75% Convertible Senior Notes due August 1, 2016 (the “3.75% Convertible Notes”) and the 3.50% Convertible Senior Notes due February 1, 2018 (the “3.50% Convertible Notes”) are included in the calculation of diluted net income per share only if their inclusion is dilutive. For the three and nine months ended March 31, 2014 and 2013, the potentially dilutive shares under the Convertible Notes were excluded from the calculation of diluted net loss per share as their inclusion would have been anti-dilutive. The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands):
		As of
		March 31,
		2014		2013
	Stock options	3,416		5,257
	RSUs, PSUs and MSUs	4,229		3,321
	3.75% Convertible Notes	10,560		10,560
	3.50% Convertible Notes	21,576		21,576
	Total	39,781		40,714
	Segment Information
	The Company has determined that it operates in only one segment, as it only reports profit and loss information on an aggregate basis to its chief operating decision maker. Revenue by geographic region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):
		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
	Americas	$	32,224		$	28,372		$	106,248		$	99,262
	Europe, Middle East, India and Africa	40,419			25,290			93,320			78,246
	Asia (excluding Japan and India)	10,096			8,496			27,762			29,154
	Japan	14,405			8,389			40,089			24,412
	Total	$	97,144		$	70,547		$	267,419		$	231,074
	Information regarding geographic areas in which the Company has long lived assets (includes all tangible assets) is as follows (in thousands):
		March 31,			June 30,
		2014			2013
	Americas	$	32,035		$	31,797
	Europe, Middle East, India and Africa	1,314			1,431
	Asia (excluding Japan and India)	421			498
	Japan	769			1,007
Total	$	34,539		$	34,733

Balance_Sheet_Components

Balance Sheet Components	9 Months Ended
	Mar. 31, 2014
Balance Sheet Components	'
Balance Sheet Components	'
	2. Balance Sheet Components
	Financing receivables
	A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset in the Company’s balance sheet. The Company’s financing receivables, consisting of its accounts receivable with contractual maturities of more than one year, were $2.8 million and $2.9 million at March 31, 2014 and June 30, 2013, respectively, and are included in Other Assets in the condensed consolidated balance sheets. There was no balance in the allowance for doubtful accounts related to such financing receivables as of March 31, 2014 and June 30, 2013, respectively.
	Inventories
	Inventories consisted of the following (in thousands):
		March 31,			June 30,
		2014			2013
	Raw materials	$	39,536		$	33,721
	Work-in-process	22,736			20,564
	Finished goods	32,816			27,307
	Inventories	$	95,088		$	81,592
	Property and equipment, net
	Property and equipment, net consisted of the following (in thousands):
		March 31,			June 30,
		2014			2013
	Furniture and fixtures	$	5,473		$	6,506
	Computer and office equipment	10,566			9,481
	Software	10,682			9,586
	Leasehold improvements	18,054			19,199
	Machinery and equipment	38,848			37,371
	Shared ownership systems	6,265			4,979
	Construction in progress	5,746			3,084
		95,634			90,206
	Less: Accumulated depreciation	(61,095		)	(55,473		)
	Property and equipment, net	$	34,539		$	34,733
	Depreciation expense related to property and equipment for the three and nine months ended March 31, 2014 was $3.0 million and $9.1 million, respectively. Depreciation expense related to property and equipment for the three and nine months ended March 31, 2013 was $3.7 million and $11.6 million, respectively.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets	'
Goodwill and Intangible Assets	'
	3. Goodwill and Intangible Assets
	Goodwill
	Activity related to goodwill consisted of the following (in thousands):
		Nine Months
		Ended			Year Ended
		March 31,			June 30,
		2014			2013
	Balance at the beginning of the period	$	59,368		$	59,215
	Addition related to acquisition	—			77
	Currency translation and other adjustments	(1,266		)	76
	Balance at the end of the period	$	58,102		$	59,368
	In connection with the acquisition of TomoTherapy in fiscal year 2011, the Company recognized liabilities related to unrecognized tax benefits as part of purchase accounting. During its first quarter of fiscal year 2014, the Company determined that certain of these liabilities related to unrecognized tax benefits were recorded in error. The Company evaluated the effects of this error on the financial statements and concluded that the error was not material to any prior annual or interim periods or the current period. In September of 2013, the Company reduced goodwill and accrued liabilities by $1.3 million to remove the liability recorded in error.
	In the second quarter of fiscal 2014, the Company performed its annual goodwill impairment test. Based on this analysis, the Company determined that there was no impairment to goodwill. The Company will continue to monitor its recorded goodwill for indicators of impairment.
	Intangible Assets
	The Company’s intangible assets associated with completed acquisitions at March 31, 2014 and June 30, 2013 are as follows (in thousands):
				March 31, 2014								June 30, 2013
				Gross								Gross
				Carrying			Accumulated			Net		Carrying		Accumulated			Net
		Useful Lives		Amount			Amortization			Amount		Amount		Amortization			Amount
		(in years)
	Developed technology	6-May		$	46,746		$	(21,240	)	$	25,506	$	46,747	$	(15,276	)	$	31,471
	Distributor license	1.5 - 2.5		2,036			(2,036		)	—		2,043		(1,618		)	425
				$	48,782		$	(23,276	)	$	25,506	$	48,790	$	(16,894	)	$	31,896
	In the quarter ended September 30, 2012, the Company recorded an impairment charge of $12.2 million relating to the CPAC in-process research and development (“IPR&D”) asset, which was presented as part of loss from discontinued operations (Note 9).
	The Company did not identify any triggering events that would indicate potential impairment of its definite-lived intangible and long-lived assets as of March 31, 2014 and June 30, 2013.
	Amortization expense related to intangible assets for the three and nine months ended March 31, 2014 was $2.0 million and $6.4 million, respectively. Amortization expense related to intangible assets for the three and nine months ended March 31, 2013 was $2.2 million and $8.2 million, respectively.
	The estimated future amortization expense of purchased intangible assets as of March 31, 2014 is as follows (in thousands):
	Year Ending June 30,	Amount
	2014 (remaining 3 months)	$	1,988
	2015	7,953
	2016	7,953
	2017	7,568
	2018	44
	Thereafter	—
		$	25,506

Financial_Instruments

Financial Instruments	9 Months Ended
	Mar. 31, 2014
Financial Instruments	'
Financial Instruments	'
	4. Financial Instruments
	The Company considers all highly liquid investments held at major banks, certificates of deposit and other securities with original maturities of three months or less to be cash equivalents.
	The Company classifies all of its investments as available-for-sale at the time of purchase because it is management’s intent that these investments are available for current operations and includes these investments on its balance sheets as short-term investments. Investments with original maturities longer than three months include commercial paper and investment-grade corporate debt securities. Investments classified as available-for-sale are recorded at fair market value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Realized gains and losses are recorded based on specific identification of each security’s cost basis.
	The Company defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three levels of inputs that may be used to measure fair value, as follows:
	Level 1— Unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date.
	Level 2— Other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including:
	·                  Quoted prices for similar assets or liabilities in active markets;
	·                  Quoted prices for identical or similar assets in non-active markets;
	·                  Inputs other than quoted prices that are observable for the asset or liability; and
	·                  Inputs that are derived principally from or corroborated by other observable market data.
	Level 3— Unobservable inputs that cannot be corroborated by observable market data and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.
	The following tables summarize the amortized cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category for cash, cash equivalents and short-term investments (in thousands):
		March 31, 2014
				Gross		Gross			Estimated Market Value
		Amortized		Unrealized		Unrealized			Cash and Cash		Short-term
		Cost		Gains		Losses			Equivalents		Investments
	Cash	$	74,736	$	—	$	—		$	74,736	$	—
	Level 1
	Certificates of deposit	9,394		—		—			9,394		—
	Money market funds	3,883		—		—			3,883		—
		13,277		—		—			13,277		—
	Level 2
	Corporate notes	86,074		38		(103		)	—		86,009
	Total	$	174,087	$	38	$	(103	)	$	88,013	$	86,009
		June 30, 2013
				Gross		Gross			Estimated Market Value
		Amortized		Unrealized		Unrealized			Cash and Cash		Short-term
		Cost		Gains		Losses			Equivalents		Investments
	Cash	$	60,082	$	—	$	—		$	60,082	$	—
	Level 1
	Certificates of deposit	15,365		—		—			12,758		2,607
	Money market funds	473		—		—			473		—
		15,838		—		—			13,231		2,607
	Level 2
	Commercial paper	3,993		—		(1		)	—		3,992
	Corporate notes	94,941		—		(456		)	—		94,485
		98,934		—		(457		)	—		98,477
	Total	$	174,854	$	—	$	(457	)	$	73,313	$	101,084
	The Company’s Level 2 investments in the table above are classified as Level 2 items because quoted prices in an active market are not readily accessible for those specific financial assets, or the Company may have relied on alternative pricing methods that do not rely exclusively on quoted prices to determine the fair value of the investments.
	The Company had investments that were in an unrealized loss position as of March 31, 2014. The Company determined that (i) it does not have the intent to sell any of these investments and (ii) it is not likely that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company reviews its investments to identify and evaluate investments that have an indication of possible impairment. As of March 31, 2014, the Company anticipates that it will recover the entire carrying value of such investments and has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the three and nine months ended March 31, 2014.
	Contractual maturities of available-for-sale securities at March 31, 2014 were as follows (in thousands):
		March 31, 2014
		Amortized		Fair Value
		Cost
	Due in 1 year or less	$	29,560	$	29,570
	Due in 1-2 years	28,559		28,552
	Due in 2-3 years	27,955		27,887
		$	86,074	$	86,009
	The following table summarizes the carrying values and estimated fair values of our long-term debt (in thousands):
		March 31, 2014				June 30, 2013
		Carrying Value		Fair Value		Carrying Value			Fair Value
	3.75% Convertible Notes	$	87,287	$	121,070	$	83,768		$	96,560
	3.50% Convertible Notes	115,000		219,989		115,000			144,302
	Total	$	202,287	$	341,059	$	198,768		$	240,862
	The long-term debt is measured on a non-recurring basis using Level 2 inputs based upon observable inputs of the Company’s underlying stock price and the time value of the conversion option, since an observable quoted price of the Convertible Notes is not readily available.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2014
Commitments and Contingencies	'
Commitments and Contingencies	'
	5. Commitments and Contingencies
	The Company’s contractual obligations were presented in the Annual Report on Form 10-K for the previous annual reporting period ended June 30, 2013. There have been no material changes outside of the ordinary course of business in those obligations during the three and nine months ended March 31, 2014.
	Litigation
	From time to time, the Company is involved in legal proceedings arising in the ordinary course of its business. Currently, management believes the Company does not have any probable and estimable losses related to any current legal proceedings and claims that would individually or in the aggregate materially adversely affect its financial condition or operating results. For certain legal proceedings, management believes that there is a reasonable possibility that losses may be incurred. Management currently estimates a range of loss (in excess of amounts accrued) between zero and $2 million in the aggregate for such legal proceedings, where it is possible to make such estimates. Litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position and cash flows.
	Best Medical Trade Secret Litigation
	On September 3, 2009, Best Medical International, Inc., or Best Medical, filed a lawsuit against the Company in the U.S. District Court for the Western District of Pennsylvania, claiming that the Company induced certain individuals to leave the employment of Best Medical and join the Company in order to gain access to Best Medical’s confidential information and trade secrets. Best Medical is seeking monetary damages and other relief. On October 25, 2011, the court presiding over the case granted summary judgment in favor of the Company on all counts. On November 21, 2011, Best Medical filed a notice of appeal. On December 22, 2011, the court awarded attorney fees and costs to the Company and ordered the Company to file an accounting of its fees and costs. Following the filing of the accounting of the Company’s fees and costs, the magistrate judge presiding over the case issued a report on the Company’s accounting and recommended an award to the Company in the amount of $512,090 in attorney fees and costs, which was adopted in its entirety by the District Court on September 27, 2013. On July 3, 2013, the Court of Appeals for the Third Circuit issued a briefing schedule for the appeal of this case. Best Medical’s brief was filed on September 16, 2013 and the Company’s brief was filed on December 30, 2013.  Best Medical filed its reply brief on January 10, 2014.  Briefing is now closed on this appeal.  Best Medical has filed a second notice of appeal of the District Court’s orders relating to the fee amount.  A briefing schedule has not yet been set for this second appeal.
	Best Medical Patent Litigation
	On August 6, 2010, Best Medical filed an additional lawsuit against the Company in the U.S. District Court for the Western District of Pennsylvania, claiming that the Company has infringed U.S. Patent No. 5,596,619, a patent that Best Medical alleges protects a method and apparatus for conformal radiation therapy. In December 2010, Best Medical amended its complaint by claiming that the Company also infringed U.S. Patent Nos. 6,038,283 and 7,266,175, both of which Best Medical alleges cover methods and apparatus for conformal radiation therapy. In March 2011, the court dismissed with prejudice all counts against the Company, except for two counts of alleged willful infringement of two of the patents. Following several procedural rulings by the court, Best Medical moved to voluntarily dismiss one of the two remaining patent claims on June 28, 2011, which the court granted on June 30, 2011, leaving only one patent (U.S. Patent No. 6,038,283) at issue in the case. The parties failed to a reach settlement during mandatory settlement conferences held in March 2013, May 2013 and April 2014. Best Medical is seeking declaratory and injunctive relief, as well as unspecified compensatory and treble damages and other relief. The Company will continue to litigate this case, and depositions of the parties’ fact witness are expected to be completed in May 2014.
	Rotary Systems
	On April 28, 2011, a former supplier to TomoTherapy, Rotary Systems Incorporated, filed suit in Minnesota state court, Tenth Judicial District, Anoka County, against TomoTherapy alleging misappropriation of trade secrets, as well as several other counts alleging various theories of injury. Rotary Systems alleges TomoTherapy misappropriated Rotary Systems’ trade secrets pertaining to a component previously purchased from Rotary Systems, which component TomoTherapy now purchases from a different supplier. The suit alleges TomoTherapy improperly supplied the alleged trade secrets to its present supplier, Dynamic Sealing Technologies Inc. (also a named defendant in the suit). Rotary Systems has made an unspecified claim for damages of greater than $50,000. TomoTherapy moved to dismiss the case on May 19, 2011, and on August 29, 2011, the court granted the motion to dismiss with respect to all counts other than the count alleging misappropriation of trade secrets. On May 21, 2012, the court granted the Company’s motion for sanctions, in part, and gave Rotary Systems sixty days to identify the alleged trade secrets with specificity or face dismissal of its claim with prejudice. The court held a hearing on September 20, 2012 to review Rotary Systems’ amended complaint and set a calendar for discovery. The court ruled on the amended complaint, and the parties have started discovery, which was originally expected to be completed by October 2013.  The parties jointly asked the court to extend discovery until February 2014.  The Company filed a motion for summary judgment and, on September 11, 2013, the court held a hearing on the Company’s motion for summary judgment and to stay discovery pending the ruling on the summary judgment motion. On December 5, 2013, the court ruled in favor of the Company. Rotary Systems filed its notice of appeal on January 29, 2014.  On April 14, 2014, Rotary Systems filed its “Brief and Addendum of Appellant” with the court.  Unless it seeks an extension, the Company’s responsive brief will be due on May 19, 2014.
	Sarif Biomedical Patent Litigation
	On January 28, 2013, Sarif Biomedical filed a patent infringement complaint against the Company in the U.S. District Court for the District of Delaware. The complaint alleges the Company’s CyberKnife System directly infringes U.S. Patent No. 5,755,725 and seeks unspecified monetary damages for the alleged infringement. Accuray filed an answer to the complaint in March 2013. The court has not yet issued a scheduling order.
	Cowealth Medical
	On February 27, 2014, Cowealth Medical Holding Co., Ltd. (“Cowealth”), Accuray’s former distributor in China, submitted a request for arbitration with the International Chamber of Commerce International Court of Arbitration (“ICC”) alleging, among other matters, that Accuray breached its distributor agreement with Cowealth by wrongfully terminating Cowealth as its distributor and misappropriated certain of Cowealth’s confidential information.  Cowealth is seeking damages and injunctive relief.  Accuray’s answer and counterclaim are due to be submitted to the ICC on May 7, 2014.  Due to the preliminary nature of this litigation, the Company is unable to determine the likelihood of an unfavorable outcome against it and is unable to reasonably estimate a range of loss, if any.
	Software License Indemnity
	Under the terms of the Company’s software license agreements with its customers, the Company agrees that in the event the software sold infringes upon any patent, copyright, trademark, or any other proprietary right of a third party, it will indemnify its customer licensees against any loss, expense, or liability from any damages that may be awarded against its customer. The Company includes this infringement indemnification in all of its software license agreements and selected managed services arrangements. In the event the customer cannot use the software or service due to infringement and the Company cannot obtain the right to use, replace or modify the license or service in a commercially feasible manner so that it no longer infringes, then the Company may terminate the license and provide the customer a refund of the fees paid by the customer for the infringing license or service. The Company has not recorded any liability associated with this indemnification, as it is not aware of any pending or threatened actions that represent probable losses as of March 31, 2014.

Acquisition

Acquisition	9 Months Ended
	Mar. 31, 2014
Acquisition	'
Acquisition	'
	6. Acquisition
	On July 16, 2012, the Company acquired the remaining 90% of the outstanding shares of Morphormics, Inc., or Morphormics, a privately-held developer of medical imaging software based in North Carolina. This acquisition enables the Company to extend auto-contouring capabilities for both the CyberKnife and TomoTherapy systems to improve disease specific workflows. The Company previously held 10% of the outstanding shares of Morphormics, which had a carrying value of zero prior to the acquisition date and was valued at $0.7 million as of the acquisition date based on the fair value of the consideration paid. The acquisition was accounted for as a business combination, and accordingly, Morphormics’ results of operations were included in the consolidated financial statements from July 16, 2012. This transaction was not considered a material business combination, and Company did not incur significant severance or acquisition-related costs in connection with the transaction.
	The fair value of total purchase consideration paid and payable for 100% of Morphormics’ equity interest as of the acquisition date was as follows (in thousands):
	Cash paid and payable	$	5,385
	Fair value of pre-existing investment in Morphormics	662
	Total	$	6,047
	The total purchase price was allocated to the net tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date as follows (in thousands):
	Cash and cash equivalents	$	668
	Accounts receivable	283
	Other current assets	7
	Amortizable intangible assets - developed technology	5,100
	Goodwill	77
	Accrued compensation	(88		)
	Total purchase price	$	6,047

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Mar. 31, 2014
Share-Based Compensation	'
Share-Based Compensation	'
	7. Share-Based Compensation
	The following table summarizes the share-based compensation charges included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):
		Three Months Ended March				Nine Months Ended March
		31,				31,
		2014		2013		2014		2013
	Cost of revenue	$	575	$	477	$	1,498	$	1,043
	Research and development	766		462		1,900		1,455
	Selling and marketing	569		256		1,483		803
	General and administrative	1,350		873		3,362		2,818
		$	3,260	$	2,068	$	8,243	$	6,119

Debt

Debt	9 Months Ended
	Mar. 31, 2014
Debt	'
Debt	'
	8. Debt
	3.75% Convertible Senior Notes due August 2016
	On August 1, 2011, the Company issued the 3.75% Convertible Notes to certain qualified institutional buyers, or QIBs. The 3.75% Convertible Notes were offered and sold to the QIBs pursuant to Rule 144A under the Securities Act of 1933, as amended, or Rule 144A. The net proceeds from the $100 million offering, after deducting the initial purchaser’s discount and commission and the related offering costs, were approximately $96.1 million. The offering costs and the initial purchaser’s discount and commission (which are recorded in Other Assets) are both being amortized to interest expense using the effective interest method over five years. The 3.75% Convertible Notes bear interest at a rate of 3.75% per year, payable semi-annually in arrears in cash on February 1 and August 1 of each year, beginning on February 1, 2012. The 3.75% Convertible Notes will mature on August 1, 2016, unless earlier repurchased, redeemed or converted.
	The 3.75% Convertible Notes were issued under an Indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Holders of the 3.75% Convertible Notes may convert their 3.75% Convertible Notes at any time on or after May 1, 2016 until the close of business on the business day immediately preceding the maturity date. Prior to May 1, 2016, holders of the 3.75% Convertible Notes may convert their 3.75% Convertible Notes only under the following circumstances: (1) during any calendar quarter after the calendar quarter ending September 30, 2011, and only during such calendar quarter, if the closing sale price of the Company’s common stock for each of 20 or more trading days in the 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 130% of the conversion price in effect on the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading-day period (such five consecutive trading-day period, the “Note Measurement Period”) in which the trading price per $1,000 principal amount of 3.75% Convertible Notes for each trading day of that Note Measurement Period was equal to or less than 98% of the product of the closing sale price of shares of the Company’s common stock and the applicable conversion rate for such trading day; (3) if the Company calls any or all of the 3.75% Convertible Notes for redemption, at any time prior to the close of business on the business day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate transactions as described in the Indenture. Upon conversion by holders of the 3.75% Convertible Notes, the Company will have the right to pay or deliver, as the case may be, cash, shares of common stock of the Company or a combination thereof, at the Company’s election. At any time on or prior to the 33rd business day immediately preceding the maturity date, the Company may irrevocably elect to (a) deliver solely shares of common stock of the Company in respect of the Company’s conversion obligation or (b) pay cash up to the aggregate principal amount of the 3.75% Convertible Notes to be converted and pay or deliver, as the case may be, cash, shares of common stock of the Company or a combination thereof in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the 3.75% Convertible Notes being converted. The initial conversion rate is 105.5548 shares of the Company’s common stock per $1,000 principal amount of 3.75% Convertible Notes (which represents an initial conversion price of approximately $9.47 per share of the Company’s common stock). The conversion rate, and thus the conversion price, are subject to adjustment as further described below.
	Holders of the 3.75% Convertible Notes who convert their 3.75% Convertible Notes in connection with a “make-whole fundamental change,” as defined in the Indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the Indenture, holders of the 3.75% Convertible Notes may require the Company to purchase all or a portion of their 3.75% Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of 3.75% Convertible Notes, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date.
	On or after August 1, 2014 and prior to the maturity date, the Company may redeem for cash all or a portion of the 3.75% Convertible Notes if the closing sale price of its common stock exceeds 130% of the applicable conversion price (the initial conversion price is approximately $9.47 per share of common stock) of such 3.75% Convertible Notes for at least 20 trading days during any consecutive 30 trading-day period (including the last trading day of such period).
	In accordance with Accounting Standards Codification, or ASC 470-20, Debt with Conversion and Other Options, the Company separately accounts for the liability and equity conversion components of the 3.75% Convertible Notes. The principal amount of the liability component of the 3.75% Convertible Notes was $75.9 million as of the date of issuance based on the present value of its cash flows using a discount rate of 10%, our approximate borrowing rate at the date of the issuance for a similar debt instrument without the conversion feature. The carrying value of the equity conversion component was $24.1 million. A portion of the initial purchaser’s discount and commission and the offering costs totaling $0.9 million was allocated to the equity conversion component. The liability component is being accreted to the principal amount of the 3.75% Convertible Notes using the effective interest method over five years.
	The following table presents the carrying value of the 3.75% Convertible Notes as of March 31, 2014 (in thousands):
		March 31,
		2014
	3.75% Convertible Note
	Carrying amount of the equity conversion component	$	23,189
	Principal amount of the 3.75% Convertible Notes	$	100,000
	Unamortized debt discount (1)	(12,713		)
	Net carrying amount	$	87,287
	(1)As of March 31, 2014, the remaining period over which the unamortized debt discount will be amortized is 28 months.
	3.50% Convertible Senior Notes due February 2018
	In February 2013, the Company issued $115.0 million aggregate principal amount of its 3.50% Convertible Notes to certain QIBs. The 3.50% Convertible Notes were offered and sold to the QIBs pursuant to Rule 144A. The net proceeds from the offering, after deducting the initial purchaser’s discount and commission and the related offering costs, were approximately $110.5 million. The offering costs and the initial purchaser’s discount and commission (which are recorded in Other Assets) are both being amortized to interest expense using the effective interest method over five years. The 3.50% Convertible Notes bear interest at a rate of 3.50% per year, payable semi-annually in arrears in cash on February 1 and August 1 of each year, beginning on August 1, 2013. The 3.50% Convertible Notes will mature on February 1, 2018, unless earlier repurchased, redeemed or converted.
	The 3.50% Convertible Notes were issued under an Indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Holders of the 3.50% Convertible Notes may convert their 3.50% Convertible Notes at any time until the close of business on the business day immediately preceding the maturity date. The 3.50% Convertible Notes are convertible, as described below, into common stock of Accuray at an initial conversion rate equal to 187.6877 shares of common stock per $1,000 principal amount of the 3.50% Convertible Notes, which is equivalent to a conversion price of approximately $5.33 per share of common stock, subject to adjustment.
	Holders of the 3.50% Convertible Notes who convert their 3.50% Convertible Notes in connection with a “make-whole fundamental change”, as defined in the Indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the Indenture, holders of the 3.50% Convertible Notes may require the Company to purchase all or a portion of their 3.50% Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of 3.50% Convertible Notes, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date.
	In accordance with guidance in ASC 470-20, Debt with Conversion and Other Options and ASC 815-15, Embedded Derivatives, the Company determined that the embedded conversion components of the 3.50% Convertible Notes did not require bifurcation and separate accounting. The $115.0 million principal amount of the 3.50% Convertible Notes has been recorded in Long-term Debt on the condensed consolidated balance sheet as of March 31, 2014.
	In April 2014, through a series of transactions, the Company refinanced approximately $70.3 million aggregate principal amount of the 3.50% Convertible Notes with approximately $70.3 million aggregate principal amount of the Company’s new 3.50% Series A Convertible Senior Notes due 2018 (the “New Notes”). In connection with such transactions, the Company also paid approximately $0.4 million in cash to the holders of the 3.50% Convertible Notes that participated in the refinancing. The New Notes have the same interest rate, maturity and other terms as the 3.50% Convertible Notes, except that the New Notes are convertible into cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the Company’s option. Following such transactions, approximately $44.7 million aggregate principal amount of the 3.50% Convertible Notes remained outstanding. See Note 12, “Subsequent Events,” for more discussion of the issuance of the New Notes in April 2014.
	A summary of interest expense related to the 3.75% Convertible Notes and the 3.50% Convertible Notes for the three and nine months ended March 31, 2014 and 2013 was as follows (in thousands):
		Three months ended					Nine months ended
		March 31,					March 31,
		2014			2013		2014		2013
	Interest expense related to contractual interest coupon	$	1,943		$	1,441	$	5,831	$	3,316
	Interest expense related to amortization of debt discount	1,205			1,093		3,519		3,192
	Interest expense related to amortization of debt issuance costs	361			226		1,053		451
		$	3,509		$	2,760	$	10,403	$	6,959

Loss_From_Discontinued_Operati

Loss From Discontinued Operations	9 Months Ended
	Mar. 31, 2014
Loss From Discontinued Operations	'
Loss From Discontinued Operations	'
	9. Loss From Discontinued Operations
	In April 2008, TomoTherapy established a new affiliate, CPAC, to develop a compact proton therapy system for the treatment of cancer. Between the date of formation of CPAC through December 2012, the Company and TomoTherapy contributed both cash and intellectual property to CPAC, resulting in a combined equity interest of approximately 15.4% of the outstanding stock of CPAC and approximately 16.3% on a fully diluted basis. As of the Company’s acquisition of TomoTherapy on June 10, 2011, the Company determined that CPAC was a variable interest entity, as CPAC depended on the Company, TomoTherapy and other investors to fund its operations. Under the accounting standards for consolidating variable interest entities, the consolidating investor is the entity with the power to direct the activities of the venture that most significantly impact the venture’s economic performance and with the obligation to absorb losses or the right to receive benefits from the venture that could potentially be significant to the venture. Although the Company and its subsidiary held less than a 50% ownership interest in CPAC, it was determined that the Company met these two characteristics, and therefore, was the primary beneficiary of CPAC. The Company consolidated the results of operations of CPAC from June 10, 2011 to December 21, 2012.
	On December 21, 2012, the Company and CPAC entered into a Purchase Agreement and Release, or Purchase Agreement, which provided for all the equity and debt investments held by the Company in CPAC to be purchased by CPAC for a nominal consideration. In addition, the Company assigned all its rights to the Dielectric Wall Accelerator technology licensed from Lawrence Livermore National Security, LLC, to CPAC. As a result of the Purchase Agreement, the Company concluded that it was no longer the primary beneficiary of CPAC since it did not have any variable interest in CPAC. In the second quarter of fiscal 2013, the Company deconsolidated CPAC and recorded a loss of $3.4 million, resulting from the write-down of the carrying value of CPAC’s net liabilities, the write-off of receivables from CPAC and the non-controlling interest in CPAC, net of cash consideration received. The results of operations of CPAC, including the loss on deconsolidation of CPAC and the losses attributable to the non-controlling interest recorded during the nine months ended March 31, 2013 have been disclosed as discontinued operations in the condensed consolidated statements of operations and comprehensive loss.

Restructuring_and_Severance_Ch

Restructuring and Severance Charges	9 Months Ended
	Mar. 31, 2014
Restructuring and Severance Charges	'
Restructuring and Severance Charges	'
	10. Restructuring and Severance Charges
	During December 2012, the Company vacated an office facility and recorded a charge of $1.4 million in general and administrative expenses during the three months ended December 31, 2012 for the remaining lease obligations on the facility, net of estimated sub-lease income. The Company also recorded a charge of $0.3 million in general and administrative expenses during the three months ended December 31, 2012 related to the disposition of certain fixed assets and leasehold improvements at this facility.
	During the three months ended December 31, 2012, the Company also recorded severance related charges of $2.2 million in general and administrative expenses due to the departure of Dr. Euan S. Thomson (former Chief Executive Officer), Mr. Chris Raanes (former Chief Operating Officer) and certain other employees.
	On January 3, 2013, the Company announced a restructuring of operations to focus on improving commercial execution and position the Company to support sustainable revenue growth and profitability. During the three months ended March 31, 2013, the Company substantially completed the restructuring exercise, reduced its global workforce under this program by 108 full-time employees and recorded $4.9 million in charges for severance and related benefits for all affected employees. Restructuring charges are reflected within general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income	'
Accumulated Other Comprehensive Income	'
	11. Accumulated Other Comprehensive Income
	The components of comprehensive loss consist of net loss, unrealized gains and losses on available-for-sale investments and foreign currency translation. The unrealized gains and losses on available-for-sale investments and foreign currency translation are excluded from earnings and reported as a component of stockholders’ equity. The foreign currency translation adjustment results from those subsidiaries not using the United States dollar as their functional currency since the majority of their economic activities are primarily denominated in their applicable local currency. Accordingly, all assets and liabilities related to these operations are translated at the current exchange rates at the end of each period. The resulting cumulative translation adjustments are recorded directly to the accumulated other comprehensive loss account in stockholders’ equity. Revenues and expenses are translated at average exchange rates in effect during the period.
	The components of accumulated other comprehensive income in the equity section of the balance sheets are as follows (in thousands):
		March 31,			June 30,
		2014			2013
	Net unrealized loss on short-term investments, net of taxes	$	(65	)	$	(457	)
	Cumulative foreign currency translation gain	2,440			2,339
	Accumulated other comprehensive income	$	2,375		$	1,882

Subsequent_events

Subsequent events	9 Months Ended
	Mar. 31, 2014
Subsequent Events	'
Subsequent Events	'
	12. Subsequent Events
	On April 17, 2014, the Company entered into note exchange agreements with certain holders (the “Participating Holders”) of the 3.50% Convertible Notes (see Note 8, “Debt”) to refinance approximately $70.3 million aggregate principal amount of the 3.50% Convertible Notes with approximately $70.3 million aggregate principal amount of the New Notes. Pursuant to the note exchange agreements, the Company also paid the Participating Holders an aggregate of approximately $0.4 million in cash in connection with such transactions. The principal amount of 3.50% Convertible Notes refinanced for each $1,000 principal amount of New Notes was $1,000 and the amount in cash paid per $1,000 principal amount of such 3.50% Convertible Notes delivered was determined in individual negotiations between the Company and each Participating Holder. The New Notes have the same interest rate, maturity and other terms as the 3.50% Convertible Notes, except that the New Notes are convertible into cash, shares of the Company’s common stock or a combination of cash and shares of common stock, at the Company’s option. Following such transactions, approximately $44.7 million aggregate principal amount of the 3.50% Convertible Notes remain outstanding.
	The $70.3 million aggregate principal amount of New Notes plus $0.4 million paid to the Participating Holders in cash will be allocated between the liability and equity conversion components of the New Notes. As a result of this allocation, the liability component will be measured based on the fair value of the New Notes which will be discounted using the Company’s market interest rate for nonconvertible debt. The residual amount will be allocated to stockholders’ equity. The discounted debt will be accreted up to its face value resulting in additional non-cash interest expense being recognized in subsequent periods within the Company’s consolidated statements of operations and comprehensive loss. As of May 7, 2014, the allocation between total liabilities and stockholders’ equity had not been finalized.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies	'
Basis of Presentation and Principles of Consolidation	'
	Basis of Presentation and Principles of Consolidation
	The condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and a variable interest entity, Compact Particle Acceleration Corporation (“CPAC”) until its deconsolidation on December 21, 2012 (for further information, see Note 9). All significant inter-company transactions and balances have been eliminated in consolidation.
	The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. The results for the three and nine months ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending June 30, 2014, for any other interim period or for any future year.
	These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the year ended June 30, 2013 included in the Company’s Annual Report on Form 10-K filed with the SEC. The Company’s significant accounting policies are described in Note 2 to those audited consolidated financial statements.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU No. 2013-11 requires that entities with an unrecognized tax benefit and a net operating loss carryforward or similar tax loss or tax credit carryforward in the same jurisdiction as the uncertain tax position present the unrecognized tax benefit as a reduction of the deferred tax asset for the loss or tax credit carryforward rather than as a liability, when the uncertain tax position would reduce the loss or tax credit carryforward under the tax law, thereby eliminating diversity in practice regarding this presentation issue. This new guidance is effective prospectively for annual reporting periods beginning on or after December 15, 2013, although retrospective application is permitted. The Company is currently assessing the impact of this guidance, if any, on its condensed consolidated financial statements.
	In March 2013, the FASB issued ASU No. 2013-05, Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. This new standard is intended to resolve diversity in practice regarding the release into net income of a cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. ASU No. 2013-05 is effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The Company is currently reviewing this standard, but it does not anticipate that its adoption will have a material impact on the Company’s condensed consolidated financial statements.
Use of Estimates	'
	Use of Estimates
	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures at the date of the financial statements. Key estimates and assumptions made by the Company relate to revenue recognition, the fair value of assets acquired and liabilities assumed in business combinations, asset impairments, inventories, share-based compensation expense, income taxes, loss contingencies and corporate bonus expenses. Actual results could differ materially from those estimates.
Concentration of Credit and Other Risks	'
	Concentration of Credit and Other Risks
	The Company’s cash, cash equivalents and investments are deposited with several major financial institutions. At times, deposits in these institutions exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances.
	For the three and nine months ended March 31, 2014 and 2013, there were no customers that represented 10% or more of total net revenue. At March 31, 2014, one customer accounted for 15% of the Company’s total accounts receivable. At June 30, 2013, one customer accounted for 10% of accounts receivable.
	Accounts receivable are typically not collateralized. The Company performs ongoing credit evaluations of its customers and maintains reserves for potential credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Accounts are charged against the allowance for doubtful accounts once collection efforts are unsuccessful.
	Single source suppliers presently provide the Company with several components. In most cases, if a supplier was unable to deliver these components, the Company believes that it would be able to find other sources for these components subject to any regulatory qualifications, if required.
Revenue Recognition	'
	Revenue Recognition
	The Company earns revenue from the sale of products, the provision of related services, which include post-contract customer support (“PCS”), installation services, training and other professional services, and the operation of its shared ownership program. The Company records its revenues net of any value added or sales tax. For arrangements with multiple elements, the Company allocates arrangement fees to product and services based upon Vendor Specific Objective Evidence (“VSOE”) of fair value of the respective elements, Third-Party Evidence (“TPE”), or Best Estimate of Selling Price (“BESP”), using the relative selling price method.
	Product and Service Revenue
	The majority of product revenue is generated from sales of CyberKnife and TomoTherapy systems. If the Company is responsible for installation, the Company recognizes revenue after installation and acceptance of the system. Otherwise, revenue is recognized upon delivery, assuming all other revenue recognition criteria are met.
	The Company could sell its systems with PCS contracts, installation services, training, and professional services. PCS contracts provide planned and corrective maintenance services, software updates, bug fixes, as well as call-center support. Service revenue is generated primarily from PCS (warranty period services and post warranty services), installation services, training, and professional services. PCS revenue is deferred and recognized over the service period. Installation service revenue is recognized concurrent with system revenue. Training and professional service revenues that are not deemed essential to the functionality of the systems are recognized as such services are performed.
	Costs associated with service revenue are expensed when incurred, except when those costs are related to system upgrades where revenue recognition has been deferred. In those cases, the costs are deferred and are recognized over the period of revenue recognition.
	Shared Ownership Program
	The Company also enters into arrangements under its shared ownership program with certain customers. These arrangements typically have a term of five years and provide the customer an option to purchase the system during the contractual term at pre-determined prices. Under the terms of this program, the Company retains title to its system, while the customer has use of the system. The Company generally receives a minimum monthly payment and earns additional revenues from the customer based upon its use of the system which are included in product revenue in the condensed consolidated statements of operations and comprehensive loss.
Net Loss Per Common Share	'
	Net Loss Per Common Share
	Basic and diluted net loss per share is computed by dividing net loss attributable to stockholders by the weighted average number of common shares outstanding during the period.
	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to stockholders follows (in thousands):
		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
	Numerator:
	Loss from operations used in computing loss per share from continuing operations	$	(4,665	)	$	(31,203	)	$	(25,639	)	$	(78,646	)
	Loss from discontinued operations used in computing loss per share from discontinued operations	$	—		$	—		$	—		$	(5,858	)
	Net loss used in computing net loss per share	$	(4,665	)	$	(31,203	)	$	(25,639	)	$	(84,504	)
	Denominator:
	Weighted average shares used in computing basic and diluted loss per share	76,382			74,016			75,447			72,953
	The potentially dilutive shares of the Company’s common stock resulting from the assumed exercise of outstanding stock options, the vesting of Restricted Stock Units (RSUs), Market Stock Units (MSUs) and Performance-based Stock Units (PSUs), and the purchase of shares under the Employee Stock Purchase Plan (ESPP), as determined under the treasury stock method, are excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive. The 3.75% Convertible Senior Notes due August 1, 2016 (the “3.75% Convertible Notes”) and the 3.50% Convertible Senior Notes due February 1, 2018 (the “3.50% Convertible Notes”) are included in the calculation of diluted net income per share only if their inclusion is dilutive. For the three and nine months ended March 31, 2014 and 2013, the potentially dilutive shares under the Convertible Notes were excluded from the calculation of diluted net loss per share as their inclusion would have been anti-dilutive. The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands):
		As of
		March 31,
		2014		2013
	Stock options	3,416		5,257
	RSUs, PSUs and MSUs	4,229		3,321
	3.75% Convertible Notes	10,560		10,560
	3.50% Convertible Notes	21,576		21,576
	Total	39,781		40,714
Segment Information	'
	Segment Information
	The Company has determined that it operates in only one segment, as it only reports profit and loss information on an aggregate basis to its chief operating decision maker. Revenue by geographic region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):
		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
	Americas	$	32,224		$	28,372		$	106,248		$	99,262
	Europe, Middle East, India and Africa	40,419			25,290			93,320			78,246
	Asia (excluding Japan and India)	10,096			8,496			27,762			29,154
	Japan	14,405			8,389			40,089			24,412
	Total	$	97,144		$	70,547		$	267,419		$	231,074
	Information regarding geographic areas in which the Company has long lived assets (includes all tangible assets) is as follows (in thousands):
		March 31,			June 30,
		2014			2013
	Americas	$	32,035		$	31,797
	Europe, Middle East, India and Africa	1,314			1,431
	Asia (excluding Japan and India)	421			498
	Japan	769			1,007
	Total	$	34,539		$	34,733

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies	'
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share	'
	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to stockholders follows (in thousands):
		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
	Numerator:
	Loss from operations used in computing loss per share from continuing operations	$	(4,665	)	$	(31,203	)	$	(25,639	)	$	(78,646	)
	Loss from discontinued operations used in computing loss per share from discontinued operations	$	—		$	—		$	—		$	(5,858	)
	Net loss used in computing net loss per share	$	(4,665	)	$	(31,203	)	$	(25,639	)	$	(84,504	)
	Denominator:
	Weighted average shares used in computing basic and diluted loss per share	76,382			74,016			75,447			72,953
Schedule of all potentially dilutive securities excluded from the computation of net loss per share	'
	The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands):
		As of
		March 31,
		2014		2013
	Stock options	3,416		5,257
	RSUs, PSUs and MSUs	4,229		3,321
	3.75% Convertible Notes	10,560		10,560
	3.50% Convertible Notes	21,576		21,576
	Total	39,781		40,714
Summary of revenue by geographic region	'
	The following summarizes revenue by geographic region (in thousands):
		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2014			2013			2014			2013
	Americas	$	32,224		$	28,372		$	106,248		$	99,262
	Europe, Middle East, India and Africa	40,419			25,290			93,320			78,246
	Asia (excluding Japan and India)	10,096			8,496			27,762			29,154
	Japan	14,405			8,389			40,089			24,412
	Total	$	97,144		$	70,547		$	267,419		$	231,074
Schedule of geographic areas in which the Company has long lived assets (includes all tangible assets)	'
	Information regarding geographic areas in which the Company has long lived assets (includes all tangible assets) is as follows (in thousands):
		March 31,			June 30,
		2014			2013
	Americas	$	32,035		$	31,797
	Europe, Middle East, India and Africa	1,314			1,431
	Asia (excluding Japan and India)	421			498
	Japan	769			1,007
	Total	$	34,539		$	34,733

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	9 Months Ended
	Mar. 31, 2014
Balance Sheet Components	'
Schedule of inventories	'
	Inventories consisted of the following (in thousands):
		March 31,			June 30,
		2014			2013
	Raw materials	$	39,536		$	33,721
	Work-in-process	22,736			20,564
	Finished goods	32,816			27,307
	Inventories	$	95,088		$	81,592
Schedule of property and equipment, net	'
	Property and equipment, net consisted of the following (in thousands):
		March 31,			June 30,
		2014			2013
	Furniture and fixtures	$	5,473		$	6,506
	Computer and office equipment	10,566			9,481
	Software	10,682			9,586
	Leasehold improvements	18,054			19,199
	Machinery and equipment	38,848			37,371
	Shared ownership systems	6,265			4,979
	Construction in progress	5,746			3,084
		95,634			90,206
	Less: Accumulated depreciation	(61,095		)	(55,473		)
	Property and equipment, net	$	34,539		$	34,733

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets	'
Schedule of goodwill	'
	Activity related to goodwill consisted of the following (in thousands):
		Nine Months
		Ended			Year Ended
		March 31,			June 30,
		2014			2013
	Balance at the beginning of the period	$	59,368		$	59,215
	Addition related to acquisition	—			77
	Currency translation and other adjustments	(1,266		)	76
	Balance at the end of the period	$	58,102		$	59,368
Schedule of intangible assets associated with completed acquisitions	'
	The Company’s intangible assets associated with completed acquisitions at March 31, 2014 and June 30, 2013 are as follows (in thousands):
				March 31, 2014								June 30, 2013
				Gross								Gross
				Carrying			Accumulated			Net		Carrying		Accumulated			Net
		Useful Lives		Amount			Amortization			Amount		Amount		Amortization			Amount
		(in years)
	Developed technology	6-May		$	46,746		$	(21,240	)	$	25,506	$	46,747	$	(15,276	)	$	31,471
	Distributor license	1.5 - 2.5		2,036			(2,036		)	—		2,043		(1,618		)	425
				$	48,782		$	(23,276	)	$	25,506	$	48,790	$	(16,894	)	$	31,896
Schedule of estimated future amortization expense of purchased intangible assets	'
	The estimated future amortization expense of purchased intangible assets as of March 31, 2014 is as follows (in thousands):
	Year Ending June 30,	Amount
	2014 (remaining 3 months)	$	1,988
	2015	7,953
	2016	7,953
	2017	7,568
	2018	44
	Thereafter	—
		$	25,506

Financial_Instruments_Tables

Financial Instruments (Tables)	9 Months Ended
	Mar. 31, 2014
Financial Instruments	'
Summary of amortized cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category for cash, cash equivalents and short-term investments	'
	The following tables summarize the amortized cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category for cash, cash equivalents and short-term investments (in thousands):
		March 31, 2014
				Gross		Gross			Estimated Market Value
		Amortized		Unrealized		Unrealized			Cash and Cash		Short-term
		Cost		Gains		Losses			Equivalents		Investments
	Cash	$	74,736	$	—	$	—		$	74,736	$	—
	Level 1
	Certificates of deposit	9,394		—		—			9,394		—
	Money market funds	3,883		—		—			3,883		—
		13,277		—		—			13,277		—
	Level 2
	Corporate notes	86,074		38		(103		)	—		86,009
	Total	$	174,087	$	38	$	(103	)	$	88,013	$	86,009
		June 30, 2013
				Gross		Gross			Estimated Market Value
		Amortized		Unrealized		Unrealized			Cash and Cash		Short-term
		Cost		Gains		Losses			Equivalents		Investments
	Cash	$	60,082	$	—	$	—		$	60,082	$	—
	Level 1
	Certificates of deposit	15,365		—		—			12,758		2,607
	Money market funds	473		—		—			473		—
		15,838		—		—			13,231		2,607
	Level 2
	Commercial paper	3,993		—		(1		)	—		3,992
	Corporate notes	94,941		—		(456		)	—		94,485
		98,934		—		(457		)	—		98,477
	Total	$	174,854	$	—	$	(457	)	$	73,313	$	101,084
Schedule of contractual maturities of available-for-sale securities	'
	Contractual maturities of available-for-sale securities at March 31, 2014 were as follows (in thousands):
		March 31, 2014
		Amortized		Fair Value
		Cost
	Due in 1 year or less	$	29,560	$	29,570
	Due in 1-2 years	28,559		28,552
	Due in 2-3 years	27,955		27,887
		$	86,074	$	86,009
Schedule of carrying values and estimated fair values of long-term debt that are measured on a non-recurring basis	'
	The following table summarizes the carrying values and estimated fair values of our long-term debt (in thousands):
		March 31, 2014				June 30, 2013
		Carrying Value		Fair Value		Carrying Value			Fair Value
	3.75% Convertible Notes	$	87,287	$	121,070	$	83,768		$	96,560
	3.50% Convertible Notes	115,000		219,989		115,000			144,302
	Total	$	202,287	$	341,059	$	198,768		$	240,862

Acquisition_Tables

Acquisition (Tables)	9 Months Ended
	Mar. 31, 2014
Acquisition	'
Schedule of components of purchase price	'
	The fair value of total purchase consideration paid and payable for 100% of Morphormics’ equity interest as of the acquisition date was as follows (in thousands):
	Cash paid and payable	$	5,385
	Fair value of pre-existing investment in Morphormics	662
	Total	$	6,047
Schedule of identifiable net tangible and intangible assets acquired and liabilities assumed in the acquisition	'
	The total purchase price was allocated to the net tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date as follows (in thousands):
	Cash and cash equivalents	$	668
	Accounts receivable	283
	Other current assets	7
	Amortizable intangible assets - developed technology	5,100
	Goodwill	77
	Accrued compensation	(88		)
	Total purchase price	$	6,047

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2014
Share-Based Compensation	'
Summary of share-based compensation charges	'
	The following table summarizes the share-based compensation charges included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):
		Three Months Ended March				Nine Months Ended March
		31,				31,
		2014		2013		2014		2013
	Cost of revenue	$	575	$	477	$	1,498	$	1,043
	Research and development	766		462		1,900		1,455
	Selling and marketing	569		256		1,483		803
	General and administrative	1,350		873		3,362		2,818
		$	3,260	$	2,068	$	8,243	$	6,119

Debt_Tables

Debt (Tables)	9 Months Ended
	Mar. 31, 2014
Debt	'
Schedule of carrying value of the 3.75% Convertible Notes	'
	The following table presents the carrying value of the 3.75% Convertible Notes as of March 31, 2014 (in thousands):
		March 31,
		2014
	3.75% Convertible Note
	Carrying amount of the equity conversion component	$	23,189
	Principal amount of the 3.75% Convertible Notes	$	100,000
	Unamortized debt discount (1)	(12,713		)
	Net carrying amount	$	87,287
	(1)As of March 31, 2014, the remaining period over which the unamortized debt discount will be amortized is 28 months.
Summary of interest expense related to the 3.75% Convertible Notes and the 3.50% Convertible Notes	'
	A summary of interest expense related to the 3.75% Convertible Notes and the 3.50% Convertible Notes for the three and nine months ended March 31, 2014 and 2013 was as follows (in thousands):
		Three months ended					Nine months ended
		March 31,					March 31,
		2014			2013		2014		2013
	Interest expense related to contractual interest coupon	$	1,943		$	1,441	$	5,831	$	3,316
	Interest expense related to amortization of debt discount	1,205			1,093		3,519		3,192
	Interest expense related to amortization of debt issuance costs	361			226		1,053		451
		$	3,509		$	2,760	$	10,403	$	6,959

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income	'
Schedule of accumulated other comprehensive income in the equity section of the balance sheets	'
	The components of accumulated other comprehensive income in the equity section of the balance sheets are as follows (in thousands):
		March 31,			June 30,
		2014			2013
	Net unrealized loss on short-term investments, net of taxes	$	(65	)	$	(457	)
	Cumulative foreign currency translation gain	2,440			2,339
	Accumulated other comprehensive income	$	2,375		$	1,882

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (Total accounts receivable, Credit concentration risk, Major customers)	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Jun. 30, 2013
	customer	customer
Total accounts receivable | Credit concentration risk | Major customers	'	'
Concentration of Credit Risk and Other Risks and Uncertainties	'	'
Number of significant customers	1	1
Percentage of concentration risk	15.00%	10.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2)	9 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies	'
Term of agreements under the shared ownership program	'5 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 3) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Aug. 02, 2011

Mar. 31, 2014

Mar. 31, 2013

Feb. 28, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

Stock options

Stock options

RSUs, PSUs and MSUs

RSUs, PSUs and MSUs

Numerator:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss from operations used in computing loss per share from continuing operations

($4,665)

($31,203)

($25,639)

($78,646)

'

'

'

'

'

'

'

'

'

'

Loss from discontinued operations used in computing loss per share from discontinued operations

'

'

'

-5,858

'

'

'

'

'

'

'

'

'

'

Net loss attributable to stockholders

($4,665)

($31,203)

($25,639)

($84,504)

'

'

'

'

'

'

'

'

'

'

Denominator:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average shares used in computing basic and diluted loss per share

76,382

74,016

75,447

72,953

'

'

'

'

'

'

'

'

'

'

Anti-dilutive securities excluded from computation of earnings per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Anti-dilutive securities excluded from the computation of diluted net loss per share (in shares)

'

'

39,781

40,714

10,560

10,560

'

21,576

21,576

'

3,416

5,257

4,229

3,321

Interest rate (as a percent)

'

'

'

'

3.75%

'

3.75%

'

'

3.50%

'

'

'

'

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 4) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013
			segment
Summary of Significant Accounting Policies	'	'	'	'	'
Number of operating segments	'	'	1	'	'
Segment Information	'	'	'	'	'
Revenue	$97,144	$70,547	$267,419	$231,074	'
Long lived assets	34,539	'	34,539	'	34,733
Americas	'	'	'	'	'
Segment Information	'	'	'	'	'
Revenue	32,224	28,372	106,248	99,262	'
Long lived assets	32,035	'	32,035	'	31,797
Europe, Middle East, India and Africa	'	'	'	'	'
Segment Information	'	'	'	'	'
Revenue	40,419	25,290	93,320	78,246	'
Long lived assets	1,314	'	1,314	'	1,431
Asia (excluding Japan and India)	'	'	'	'	'
Segment Information	'	'	'	'	'
Revenue	10,096	8,496	27,762	29,154	'
Long lived assets	421	'	421	'	498
Japan	'	'	'	'	'
Segment Information	'	'	'	'	'
Revenue	14,405	8,389	40,089	24,412	'
Long lived assets	$769	'	$769	'	$1,007

Balance_Sheet_Components_Detai

Balance Sheet Components (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013
Financing receivables	'	'	'	'	'
Accounts receivable with contractual maturities of more than one year	$2,800,000	'	$2,800,000	'	$2,900,000
Allowance for doubtful financing receivable accounts related to financing receivables	0	'	0	'	0
Inventories	'	'	'	'	'
Raw materials	39,536,000	'	39,536,000	'	33,721,000
Work-in-process	22,736,000	'	22,736,000	'	20,564,000
Finished goods	32,816,000	'	32,816,000	'	27,307,000
Total inventories	95,088,000	'	95,088,000	'	81,592,000
Property and Equipment, net	'	'	'	'	'
Property and equipment, gross	95,634,000	'	95,634,000	'	90,206,000
Less: Accumulated depreciation and amortization	-61,095,000	'	-61,095,000	'	-55,473,000
Property and equipment, net	34,539,000	'	34,539,000	'	34,733,000
Depreciation and amortization expense	3,000,000	3,700,000	9,100,000	11,600,000	'
Furniture and fixtures	'	'	'	'	'
Property and Equipment, net	'	'	'	'	'
Property and equipment, gross	5,473,000	'	5,473,000	'	6,506,000
Computer and office equipment	'	'	'	'	'
Property and Equipment, net	'	'	'	'	'
Property and equipment, gross	10,566,000	'	10,566,000	'	9,481,000
Software	'	'	'	'	'
Property and Equipment, net	'	'	'	'	'
Property and equipment, gross	10,682,000	'	10,682,000	'	9,586,000
Leasehold improvements	'	'	'	'	'
Property and Equipment, net	'	'	'	'	'
Property and equipment, gross	18,054,000	'	18,054,000	'	19,199,000
Machinery and equipment	'	'	'	'	'
Property and Equipment, net	'	'	'	'	'
Property and equipment, gross	38,848,000	'	38,848,000	'	37,371,000
Shared ownership systems	'	'	'	'	'
Property and Equipment, net	'	'	'	'	'
Property and equipment, gross	6,265,000	'	6,265,000	'	4,979,000
Construction in progress	'	'	'	'	'
Property and Equipment, net	'	'	'	'	'
Property and equipment, gross	$5,746,000	'	$5,746,000	'	$3,084,000

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2014

TomoTherapy

IPR&D technology carried out by CPAC

Developed technology

Developed technology

Developed technology

Developed technology

Distributor license

Distributor license

Distributor license

Distributor license

Liabilities related to unrecognized tax

Minimum

Maximum

Minimum

Maximum

Changes in the carrying amount of goodwill

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the period

'

'

$59,368,000

$59,215,000

$59,215,000

$1,300,000

'

'

'

'

'

'

'

'

'

Addition related to acquisition

'

'

'

'

77,000

'

'

'

'

'

'

'

'

'

'

Currency translation and other adjustment

'

'

-1,266,000

'

76,000

'

'

'

'

'

'

'

'

'

'

Balance at the end of the period

58,102,000

'

58,102,000

'

59,368,000

1,300,000

'

'

'

'

'

'

'

'

'

Impairment of goodwill

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible Assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

58,102,000

'

58,102,000

'

59,368,000

1,300,000

'

'

'

'

'

'

'

'

'

Accrued liabilities

'

'

'

'

'

1,300,000

'

'

'

'

'

'

'

'

'

Useful Lives

'

'

'

'

'

'

'

'

'

'5 years

'6 years

'

'

'1 year 6 months

'2 years 6 months

Gross Carrying Amount, Finite Lived Intangibles

'

'

'

'

'

'

'

46,746,000

46,747,000

'

'

2,036,000

2,043,000

'

'

Total gross carrying amount

48,782,000

'

48,782,000

'

48,790,000

'

'

'

'

'

'

'

'

'

'

Accumulated Amortization

-23,276,000

'

-23,276,000

'

-16,894,000

'

'

-21,240,000

-15,276,000

'

'

-2,036,000

-1,618,000

'

'

Net Amount, Finite Lived Intangibles

25,506,000

'

25,506,000

'

31,896,000

'

'

25,506,000

31,471,000

'

'

'

425,000

'

'

Impairment charge recorded due to a decrease in projected future usage of the technology

'

'

'

12,200,000

'

'

12,200,000

'

'

'

'

'

'

'

'

Amortization expense

2,000,000

2,200,000

6,400,000

8,200,000

'

'

'

'

'

'

'

'

'

'

'

Estimated future amortization expense of purchased intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014 (remaining 3 months)

1,988,000

'

1,988,000

'

'

'

'

'

'

'

'

'

'

'

'

2015

7,953,000

'

7,953,000

'

'

'

'

'

'

'

'

'

'

'

'

2016

7,953,000

'

7,953,000

'

'

'

'

'

'

'

'

'

'

'

'

2017

7,568,000

'

7,568,000

'

'

'

'

'

'

'

'

'

'

'

'

2018

44,000

'

44,000

'

'

'

'

'

'

'

'

'

'

'

'

Net Amount, Finite Lived Intangibles

$25,506,000

'

$25,506,000

'

$31,896,000

'

'

$25,506,000

$31,471,000

'

'

'

$425,000

'

'

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2012
Cash, cash equivalents and short-term investments	'	'	'	'	'
Cash	$74,736	$74,736	$60,082	'	'
Amortized Cost	86,074	86,074	'	'	'
Gross Unrealized Gains	38	38	'	'	'
Gross Unrealized Losses	-103	-103	-457	'	'
Available-for-sale Securities	86,009	86,009	'	'	'
Total Amortized Cost	174,087	174,087	174,854	'	'
Cash and Cash Equivalents	88,013	88,013	73,313	181,526	143,504
Short-term investments	86,009	86,009	101,084	'	'
Other-than-temporary impairments associated with credit losses	0	0	'	'	'
Amortized Cost	'	'	'	'	'
Due in 1 year or less	29,560	29,560	'	'	'
Due in 1-2 years	28,559	28,559	'	'	'
Due in 2-3 years	27,955	27,955	'	'	'
Amortized cost	86,074	86,074	'	'	'
Fair Value	'	'	'	'	'
Due in 1 year or less	29,570	29,570	'	'	'
Due in 1-2 years	28,552	28,552	'	'	'
Due in 2-3 years	27,887	27,887	'	'	'
Available-for-sale Securities	86,009	86,009	'	'	'
Level 1	'	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'	'
Cash Equivalents	13,277	13,277	13,231	'	'
Cash Equivalents and Short-term Investments including Available-for-sale Securities	13,277	13,277	15,838	'	'
Available-for-sale Securities	'	'	2,607	'	'
Fair Value	'	'	'	'	'
Available-for-sale Securities	'	'	2,607	'	'
Level 1 | Certificates of deposits	'	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'	'
Cash Equivalents	9,394	9,394	12,758	'	'
Cash Equivalents and Short-term Investments including Available-for-sale Securities	9,394	9,394	15,365	'	'
Available-for-sale Securities	'	'	2,607	'	'
Fair Value	'	'	'	'	'
Available-for-sale Securities	'	'	2,607	'	'
Level 1 | Money market funds	'	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'	'
Cash Equivalents	3,883	3,883	473	'	'
Level 2	'	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'	'
Amortized Cost	'	'	98,934	'	'
Gross Unrealized Losses	'	'	-457	'	'
Available-for-sale Securities	'	'	98,477	'	'
Amortized Cost	'	'	'	'	'
Amortized cost	'	'	98,934	'	'
Fair Value	'	'	'	'	'
Available-for-sale Securities	'	'	98,477	'	'
Level 2 | Commercial paper	'	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'	'
Amortized Cost	'	'	3,993	'	'
Gross Unrealized Losses	'	'	-1	'	'
Available-for-sale Securities	'	'	3,992	'	'
Amortized Cost	'	'	'	'	'
Amortized cost	'	'	3,993	'	'
Fair Value	'	'	'	'	'
Available-for-sale Securities	'	'	3,992	'	'
Level 2 | Corporate notes	'	'	'	'	'
Cash, cash equivalents and short-term investments	'	'	'	'	'
Amortized Cost	86,074	86,074	94,941	'	'
Gross Unrealized Gains	38	38	'	'	'
Gross Unrealized Losses	-103	-103	-456	'	'
Available-for-sale Securities	86,009	86,009	94,485	'	'
Amortized Cost	'	'	'	'	'
Amortized cost	86,074	86,074	94,941	'	'
Fair Value	'	'	'	'	'
Available-for-sale Securities	$86,009	$86,009	$94,485	'	'

Financial_Instruments_Details_

Financial Instruments (Details 2) (USD $)

Mar. 31, 2014

Aug. 02, 2011

Feb. 28, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2013

In Thousands, unless otherwise specified

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Non-recurring basis

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Carrying Value

Fair Value

Fair Value

Fair Value

Fair Value

Fair Value

Fair Value

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

Fair value measurement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long term debt

'

'

'

$202,287

$198,768

$87,287

$83,768

$115,000

$115,000

$341,059

$240,862

$121,070

$96,560

$219,989

$144,302

Interest rate (as a percent)

3.75%

3.75%

3.50%

'

'

3.75%

3.75%

3.50%

3.50%

'

'

3.75%

3.75%

3.50%

3.50%

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	Mar. 31, 2014	Sep. 27, 2013	Jun. 30, 2011	Mar. 31, 2011	21-May-12	Apr. 30, 2011
		Best Medical Trade Secret Litigation	Best Medical Patent Litigation	Best Medical Patent Litigation	Rotary Systems	Rotary Systems
			claim	counts		Minimum
			counts	patent
Contingencies	'	'	'	'	'	'
Estimated loss, low end range	$0	'	'	'	'	'
Estimated loss, high end range	2,000,000	'	'	'	'	'
Attorney fees and costs receivable	'	512,090	'	'	'	'
Number of counts of alleged willful infringement of patents	'	'	'	2	'	'
Number of patents against which lawsuit is not dismissed	'	'	1	2	'	'
Number of patent claims dismissed	'	'	1	'	'	'
Claim for damages	'	'	'	'	'	$50,000
Period to identify alleged trade secrets with specificity or face dismissal of claim with prejudice	'	'	'	'	'60 days	'

Acquisition_Details

Acquisition (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013	Jun. 30, 2012	Jul. 16, 2012	Jun. 30, 2012
In Thousands, unless otherwise specified				Morphormics	Morphormics
Acquisition	'	'	'	'	'
Acquisition of remaining outstanding shares (as a percent)	'	'	'	90.00%	'
Outstanding shares held prior to acquisition (as a percent)	'	'	'	10.00%	'
Fair value of outstanding shares prior to acquisition	'	'	'	$662	$0
Total acquired equity interest (as a percent)	'	'	'	100.00%	'
Fair value of total purchase consideration paid and payable	'	'	'	'	'
Cash paid and payable	'	'	'	5,385	'
Fair value of pre-existing investment in Morphormics	'	'	'	662	0
Total purchase price	'	'	'	6,047	'
Purchase price allocation	'	'	'	'	'
Cash and cash equivalents	'	'	'	668	'
Accounts receivable	'	'	'	283	'
Other current assets	'	'	'	7	'
Amortizable intangible assets - developed technology	'	'	'	5,100	'
Goodwill	58,102	59,368	59,215	77	'
Accrued compensation	'	'	'	-88	'
Total purchase price	'	'	'	$6,047	'

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Share-based compensation charges	'	'	'	'
Share-based compensation expense	$3,260	$2,068	$8,243	$6,119
Cost of revenue	'	'	'	'
Share-based compensation charges	'	'	'	'
Share-based compensation expense	575	477	1,498	1,043
Research and development	'	'	'	'
Share-based compensation charges	'	'	'	'
Share-based compensation expense	766	462	1,900	1,455
Selling and marketing	'	'	'	'
Share-based compensation charges	'	'	'	'
Share-based compensation expense	569	256	1,483	803
General and administrative	'	'	'	'
Share-based compensation charges	'	'	'	'
Share-based compensation expense	$1,350	$873	$3,362	$2,818

Debt_Details

Debt (Details) (USD $)

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Aug. 02, 2011

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Feb. 28, 2013

Mar. 31, 2014

Apr. 17, 2014

Apr. 30, 2014

Jun. 30, 2014

Apr. 30, 2014

Apr. 17, 2014

3.75% Convertible Note and 3.50% Convertible Note

3.75% Convertible Note and 3.50% Convertible Note

3.75% Convertible Note and 3.50% Convertible Note

3.75% Convertible Note and 3.50% Convertible Note

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.75% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

3.50% Convertible Notes

New Notes

New Notes

New Notes

Minimum

Maximum

Subsequent event

Subsequent event

Subsequent event

Subsequent event

Subsequent event

Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount of debt issued

'

'

'

'

'

'

'

$100,000,000

'

'

'

$115,000,000

'

'

'

'

$70,300,000

$70,300,000

Interest rate (as a percent)

'

'

'

'

'

'

'

3.75%

3.75%

'

'

3.50%

'

3.50%

3.50%

3.50%

3.50%

'

Cash paid to Participating Holders in connection with debt refinancing

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

400,000

'

'

'

Aggregate principal amount of debt refinanced

'

'

'

'

'

'

'

'

'

'

'

'

'

70,300,000

70,300,000

'

'

'

Principal amount of the Notes

'

'

'

'

'

'

'

75,900,000

100,000,000

'

'

'

'

44,700,000

44,700,000

'

'

'

Proceeds from debt, net of costs

'

'

'

'

'

'

'

96,100,000

'

'

'

110,500,000

'

'

'

'

'

'

Debt issuance costs, amortization period

'

'

'

'

'

'

'

'5 years

'

'

'

'5 years

'

'

'

'

'

'

Conversion rate, number of shares to be issued per $1000 of principal amount (in shares)

'

'

'

'

'

'

'

'

105.5548

'

'

'

187.6877

'

'

'

'

'

Principal amount used for debt instrument conversion ratio

'

'

'

'

'

'

'

'

1,000

'

'

'

1,000

'

'

'

'

'

Conversion price (in dollars per share)

'

'

'

'

'

'

'

'

$9.47

'

'

'

$5.33

'

'

'

'

'

Number of days within 30 consecutive trading days in which the closing price of the entity's common stock must exceed the conversion price for the notes to be convertible into common stock

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'

Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be convertible into common stock

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

Percentage of the closing sales price of the entity's common stock that the conversion price must exceed in order for the notes to be convertible

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

'

Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period

'

'

'

'

'

'

'

'

'5 days

'

'

'

'

'

'

'

'

'

Number of consecutive trading days before five consecutive business days during the note measurement period

'

'

'

'

'

'

'

'

'5 days

'

'

'

'

'

'

'

'

'

Percentage of the trading price to the product of the sale price of the entity's common stock and the conversion rate

'

'

'

'

'

'

'

'

'

'

98.00%

'

'

'

'

'

'

'

Number of working days preceding maturity date for delivery of shares or payment of cash

'

'

'

'

'

'

'

'

'33 days

'

'

'

'

'

'

'

'

'

Repurchase price, as percentage of principal amount, if company undergoes change of control

'

'

'

'

'

'

'

'

100.00%

'

'

'

100.00%

'

'

'

'

'

Percentage of the closing sales price of the entity's common stock that the conversion price must exceed in order for the notes to be redeemable

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

'

Number of days within 30 consecutive trading days in which the closing price of the entity's common stock must exceed the conversion price for the notes to be redeemable

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'

Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be redeemable

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

Discount rate on liability component (as a percent)

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

Debt issuance costs and discount allocated to equity conversion component

'

'

'

'

'

'

'

900,000

'

'

'

'

'

'

'

'

'

'

Carrying amount of the equity conversion component

'

'

'

'

'

'

'

24,100,000

23,189,000

'

'

'

'

'

'

'

'

'

Unamortized debt discount

'

'

'

'

'

'

'

'

-12,713,000

'

'

'

'

'

'

'

'

'

Net carrying amount

202,287,000

'

198,768,000

'

'

'

'

'

87,287,000

'

'

'

'

'

'

'

'

'

Amortization period

'

'

'

'

'

'

'

'

'28 months

'

'

'

'

'

'

'

'

'

Interest expense related to contractual interest coupon

'

'

'

1,943,000

1,441,000

5,831,000

3,316,000

'

'

'

'

'

'

'

'

'

'

'

Interest expense related to amortization of debt discount

'

'

'

1,205,000

1,093,000

3,519,000

3,192,000

'

'

'

'

'

'

'

'

'

'

'

Interest expense related to amortization of debt issuance costs

1,053,000

451,000

'

361,000

226,000

1,053,000

451,000

'

'

'

'

'

'

'

'

'

'

'

Total interest expense recognized

'

'

'

$3,509,000

$2,760,000

$10,403,000

$6,959,000

'

'

'

'

'

'

'

'

'

'

'

Loss_From_Discontinued_Operati1

Loss From Discontinued Operations (Details) (USD $)	9 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012
		CPAC	CPAC
Investment in CPAC	'	'	'
Ownership interest (as a percent)	'	'	15.40%
Ownership interest on fully diluted basis (as a percent)	'	'	16.30%
Loss on deconsolidation of a consolidated variable interest entity	$3,442	$3,400	'

Restructuring_and_Severance_Ch1

Restructuring and Severance Charges (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
	item
Office facility	'	'
Restructuring and Severance Charges	'	'
Restructuring charges	'	$1.40
Disposition of fixed assets and leasehold improvements	'	'
Restructuring and Severance Charges	'	'
Restructuring charges	'	0.3
Employee severance	'	'
Restructuring and Severance Charges	'	'
Charges for severance and related benefits	$4.90	$2.20
Number of full-time employees reduced	108	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Accumulated Other Comprehensive Income	'	'
Net unrealized loss on short-term investments, net of taxes	($65)	($457)
Cumulative foreign currency translation gain	2,440	2,339
Accumulated other comprehensive income	$2,375	$1,882

Subsequent_events_Details

Subsequent events (Details) (USD $)	Feb. 28, 2013	Apr. 17, 2014	Apr. 30, 2014	Jun. 30, 2014	7-May-14	Apr. 17, 2014	Jun. 30, 2014	Apr. 30, 2014
	3.50% Convertible Notes	Subsequent event	Subsequent event	Subsequent event	Subsequent event	Subsequent event	Subsequent event	Subsequent event
		3.50% Convertible Notes	3.50% Convertible Notes	3.50% Convertible Notes	3.50% Convertible Notes	New Notes	New Notes	New Notes
Subsequent events	'	'	'	'	'	'	'	'
Interest rate (as a percent)	3.50%	3.50%	3.50%	'	'	'	3.50%	3.50%
Aggregate principal amount of debt issued	$115,000,000	'	'	'	'	$70,300,000	'	$70,300,000
Cash paid to Participating Holders in connection with debt refinancing	'	400,000	400,000	'	'	'	'	'
Aggregate principal amount of debt refinanced	'	70,300,000	70,300,000	'	'	'	'	'
Aggregate principal amount of debt outstanding	'	44,700,000	44,700,000	'	'	'	'	'
Conversion rate, principal amount of new debt to be issued per principal amount of 3.50% Convertible Notes	'	'	'	'	'	1	'	'
Principal amount of debt used as basis for payment of cash	'	1,000	'	'	'	'	'	'
Aggregate amount paid on exchange of debt	'	'	'	70,700,000	'	'	'	'
Amount of which allocation between total liabilities and shareholders' equity had not been finalized	'	'	'	'	$70,400,000	'	'	'